Assessment of Platelet-derived GARP in Atherosclerotic Disease (CAPGAD)

January 23, 2026 updated by: Université Catholique de Louvain
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Belgium
      • Brussels, Belgium, 1200
        • Cliniques Universitaires Saint-luc
        • Contact:
        • Principal Investigator:
          • Christophe Beauloye, Medical Degree
        • Sub-Investigator:
          • Louis Charki, Medical Degree
        • Sub-Investigator:
          • Maxime Elens, Medical Degree

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population will comprise patients undergoing femoral or carotid endarterectomy in our tertiary care center (Cliniques Universitaires Saint-Luc) for atherosclerotic disease who do not meet exclusion criteria.

Description

Inclusion Criteria:

  • Older than 18 years
  • Able to give informed consent
  • Undergoing carotid or femoral endarterectomy

Exclusion Criteria:

  • Younger than 18 years
  • Pregnant
  • Dialysis
  • Unable to give informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Endarterectomy population
This group includes patients with significant atherosclerotic burden justifying a surgical intervention of carotid or femoral endarterectomy.
Other: Tissue sample and data collection
Tissue sample and data collection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
GARP Expression in Platelets
Time Frame: Throughout the entire study, approximately during 3 years
The number of cells/area expressing the GARP protein will be assessed
Throughout the entire study, approximately during 3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
GARP Expression T Regulating Cells
Time Frame: Throughout the entire study, approximately during 3 years
The number of cells expressing GARP will be assessed as a number of cells / area
Throughout the entire study, approximately during 3 years
GARP Expression General
Time Frame: Throughout the entire study, approximately during 3 years
The type of cells expressing GARP will be assessed as a number of cells / area
Throughout the entire study, approximately during 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Université Catholique de Louvain

Collaborators

Fonds National de la Recherche Scientifique

Investigators

  • Principal Investigator: Christophe Beauloye, Medical Degree, Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2026

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

January 1, 2029

Study Registration Dates

First Submitted

January 15, 2026

First Submitted That Met QC Criteria

January 15, 2026

First Posted (Actual)

January 23, 2026

Study Record Updates

Last Update Posted (Actual)

January 27, 2026

Last Update Submitted That Met QC Criteria

January 23, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CAPGAD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atheroma; Carotid Artery

Clinical Trials on Tissue sample and data collection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe